News & Updates

Tumour necrosis factor (TNF)-α antagonists show comparable safety as non-TNF biologics in the treatment of inflammatory bowel disease (IBD) in patients with active or recent cancer, as shown in a study.

A diagnosis of lung cancer can significantly worsen survival in patients with idiopathic pulmonary fibrosis (IPF), reports a study.

Using a 4-day, fixed-dose schedule of filgrastim as granulocyte-colony stimulating factor (G-CSF) primary prophylaxis reduces the incidence of febrile neutropenia (FN) and associated hospitalization while maintaining the doses of adjuvant docetaxel and cyclophosphamide (TC) among Chinese women with early breast cancer (BC), a retrospective cohort study in Hong Kong has shown.

Magnetic resonance imaging (MRI) guidance in stereotactic body radiotherapy (SBRT) for prostate cancer offers significant advantage over computed tomography (CT) guidance, with lower physician-scored toxic effects and patient-reported symptom burden, according to the results of the phase III MIRAGE* study.

START-FIT, a prospective, single-arm, phase II trial, has found sequential transarterial chemoembolization (TACE) and stereotactic body radiotherapy (SBRT) followed by anti–PD-L1 treatment with avelumab to be a promising strategy for making patients with locally advanced unresectable hepatocellular carcinoma (HCC) amenable to curative treatment.